Table S1: Antibodies Used for Flow Cytometric Analysis

Table S2: Contemporaneous Control Cohort/Std Rx Cohort Characteristics Age Average Age 48 Years Sex % Male 41% Primary Disease % AML 50% % ALL 14% % Other Primary Disease 36% HLA % HLA matched 77% Conditioning Regimen % Bu/Cy % TBI/Cy 18% % Flu/Mel 46% Graft Type % PBMC Grafts 91% Neutrophil Engraftment Mean Day of Neutrophil Engraftment 16 days CD4 Reconstitution Day 100 CD4+ T cell Count 282 +/- 44 cells/ml GVHD % Grade II-IV AGVHD Prior to Day 100 % III-IV AGVHD Prior to Day 100 17% % Receiving GVHD Salvage Therapy Relapse % Relapse Survival % Surviving at 18 months post-transplant 72% Table S2 Need % males and Day 100 CD4+ T cell count

Table S3: StdRx Patient and Transplant Characteristics UPN Age/Sex Disease and Status HLA matching (mismatch) CMV Status (R/D) Preparative Regimen Graft Source 003-001 30 ALL, primary induction failure 8/8 +/- Bu/Cy PBSC 003-002 35 Myelofibrosis 7/8 (A antigen) -/+ 003-003 66 MDS +/+ Flu/Mel 003-004 48 Chronic phase CML, TKI resistant/intolerant 7/8 (C antigen) 64 ALL, CR2 TBI/Cy 003-006 41 7/8 (B antigen) Bu/Cy/ATG 004-001 12 ALL, CR1 TBI/Cy/VP16 BM Table S3

Table S4 StdRx Clinical Outcomes

100% XY. 97.5% XX. Grade II AGvHD involving the skin on d+48. Grade III AGvHD involving the gut d+35, steroid refractory, treated with infliximab. Grade IV AGvHD involving the skin, liver, and gut, steroid refractory, treated with infliximab. Grade III AGvHD involving the gut on d+44, steroid refractory, treated with infliximab. Atypical pneumonia d+12. Parainfluenza – not intubated, not requiring ICU stay on d+10; enterobacter bacteremia – requiring hospitalization and IV abx on d+117.